Strategic Partnerships

Over the past several years, CureVac has entered into various collaborations with strong and competent partners who all share the same goal: to develop a completely new RNA-based treatment regimen and make it available to patients.

Below are some selected collaborations.

Collaboration with Arcturus Therapeutics

CureVac has entered into a broad strategic collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, to jointly develop up to four molecular therapy products for rare diseases using CureVac’s optimized natural mRNA sequence and Arcturus’s lipid-mediated nucleic acid delivery system. Furthermore, the collaboration also grants CureVac access to the full suite of Arcturus’s lipid-mediated delivery intellectual property to enable the development of additional mRNA product candidates.

For more details please see the press release announcing the start of the collaboration on January 4, 2018.

Collaboration with CRISPR Therapeutics and Casebia Therapeutics

CureVac collaborates with CRISPR Therapeutics, a genome editing company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therapeutics in select disease areas. Under the terms of the agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.

For more details please see the press release announcing the start of the collaboration on November 13, 2017.

Collaboration with Lilly

Lilly and CureVac collaborate on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use CureVac's mRNA technology that targets tumor neoantigens for a more robust anti-cancer immune response.

This transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

For more details please see the press release announcing the start of the collaboration on October 18, 2017.

Collaboration with Boehringer Ingelheim

The partners collaborate to develop next generation lung cancer immunotherapy with CureVac’s CV9202 in different clinical settings. CureVac received EUR 35 million upfront payment and can achieve milestone payments of up to EUR 430 million and royalties on sales.

For more details please see the press release announcing the start of the collaboration on September 18, 2014.

Collaboration with the Bill & Melinda Gates Foundation

Common goal of the partners is to develop mRNA-based vaccines against various infectious diseases which have an enormous impact on global health.

Read the press release on the initiation of the RSV programme on August 4, 2015.

Read the press release on the awarding of two new grants to pursue mRNA vaccines against flu and malaria on February 13, 2018.

Collaboration with Cancer Research Institute and Ludwig Cancer Research

The non-profit Cancer Research Institute (CRI), Ludwig Cancer Research (Ludwig) and CureVac collaborate to enable clinical testing of novel cancer immunotherapy treatment options. The partnership focusses on clinical trials to test novel combinations of immunotherapies, including CureVac's clinical stage drug CV9202 for non-small cell lung cancer.

For more details please see the press release on the start of the collaboration on November 4, 2013.